XENE
Xenon Pharmaceuticals Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow -7.9% ·
net new positions -7.1%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 130 | $5,069 | n/a | n/a |
| Q2 2026 | 113 | +7 | 55.63M | $3.35B | +11 | −5 |
| Q1 2026 | 110 | +12 | 59.13M | $3.41B | +18 | −6 |
| Q4 2025 | 96 | 0 | 51.65M | $2.31B | +1 | −1 |
| Q3 2025 | 17 | 0 | 29.02M | $1.17B | n/a | n/a |
| Q2 2025 | 14 | -1 | 23.81M | $745.12M | +1 | −2 |
| Q1 2025 | 12 | +1 | 10.74M | $360.22M | +1 | n/a |
| Q4 2024 | 11 | -1 | 10.24M | $401.45M | n/a | −1 |
| Q3 2024 | 11 | 0 | 11.68M | $459.86M | n/a | n/a |
| Q2 2024 | 11 | n/a | 11.68M | $455.36M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 8.88M | n/a | $278.08M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 5.37M | n/a | $167.93M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 3 | Wellington Management ✦ | 2.17M | -42.6% | $68.07M | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
| 4 | State Street Global Advisors ✦ (passive) | 1.38M | +351.7% | $43.21M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 1.29M | -32.6% | $40.38M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 6 | Marshall Wace ✦ | 1.02M | +34.6% | $31.93M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 970.34K | +1294.2% | $30.37M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Millennium Management ✦ | 882.84K | +277.2% | $27.63M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 9 | The Vanguard Group ✦ (passive) | 873.23K | n/a | $27.33M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 10 | Capital World Investors ✦ | 655.74K | -70.5% | $20.52M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 141.78K | -6.8% | $4.44M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 120.05K | -82.5% | $3.76M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 37.94K | New | $1.19M | 0.0% | New | 1 | SEC ↗ ×2 |
| 14 | Renaissance Technologies ✦ | 8.60K | -94.4% | $269,180 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| T. Rowe Price | $1.19M | 0.0% |
Exited
| Two Sigma Investments | $7.95M | was 0.0% |
| Point72 Asset Management | $7.04M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 289 holders, 98.30M shares, $5.52B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · Chief Financial… · 15.00K sh @ 37.32 · $559,740
Officer, Director · PRESIDENT & CEO · 30.00K sh @ 37.38 · $1.12M
Open-market sales (S)
Officer · 6.37K sh · $383,145
Officer · 700 sh · $42,684
Director · 10.00K sh · $640,550
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology